R-FCM + maintenance R

Regimen

R-FCM followed by Rituximab 375 mg/m2 iv qw x 4 doses at 3 and 9 months

References

Forstpointner R et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108:4003